Ocular Drug Delivery Devices Market

Ocular Drug Delivery Devices Market Overview

The global ocular drug delivery devices market, valued at USD 964 million in 2025, is projected to reach USD 1,098 million in 2026 and USD 1,616 million by 2030, with a 10.1% CAGR during the forecast period 2026 to 2030.

To learn more about this report, request a free sample copy

According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented.

It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss.

Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability enhancement at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.

Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices for ophthalmic route, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of ophthalmologic medications and eye drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in ocular drug delivery devices market. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady market growth during the forecast period.

Key Companies in Ocular Drug Delivery Devices Market 

Examples of key companies engaged in ocular drug delivery devices market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alimera Sciences, Bausch and Lomb, EyePoint Pharmaceuticals, Genentech, Glaukos, Neurotech Pharmaceuticals and Ocular Therapeutix. This market report includes an easily searchable excel database of all the companies providing ophthalmic / ocular drug delivery devices, worldwide.

Recent Developments in Ocular Drug Delivery Devices Market:

Several recent developments have taken place in the field of ocular drug delivery devices market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2023, Eyenovia announced FDA approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis leveraging the proprietary Optejet® device platform.

Scope of the Report

The “Ocular Drug Delivery Devices Market by Type of Drug Delivery Device (Implants, Inserts and Punctal Plugs), Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet Age-related Macular Degeneration, Retinal Diseases, Neovascular Age-Related Macular Degeneration and Others), Type of Product (Biodegradable and Non-biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, Till 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the ocular drug delivery devices market. The market research report features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the market research report includes:

• A detailed assessment of the current market landscape of novel ocular drug delivery devices, with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I / II, phase I and preclinical), type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).
• Elaborate profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.
• An in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.
• An analysis of the partnerships that have been established in ocular drug delivery devices market during the period, till 2021 covering R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and other related agreements.
• An analysis of the investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
• An in-depth analysis of over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  
• A case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers and others.

The key objective of ocular drug delivery devices market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for ocular drug delivery devices market during the forecast period. Additionally, it features market size projections for the overall ocular drug delivery devices market, wherein both the current and upcoming opportunity is segmented across [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indications (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable  and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
 
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in ocular drug delivery devices market. The market research report features detailed transcripts of interviews held with the following individuals:

• Chief Executive Officer and Founder, Small Company, Israel
• Chief Executive Officer and Co-founder, Small Company, US

Frequently Asked Questions

Question 1: What are ocular drug delivery systems?

Answer: Ocular drug delivery systems belong to a novel class of drug administrating devices for minimally invasive dosing of ophthalmic drugs, providing a better patient response and comfort.

Question 2: How big is the ocular drug delivery devices market?

Answer: The ocular drug delivery devices market size is estimated to be worth $ 1,098 million in 2026.

Question 3: What is the projected market growth of the ocular drug delivery devices market?

Answer: The ocular drug delivery devices market is expected to grow at compounded annual growth rate (CAGR) of 10.1% during the forecast period.

Question 4: Who are the leading companies in the ocular drug delivery devices market?

Answer: Examples of key companies engaged in developing ocular drug delivery devices (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alimera Sciences, Bausch and Lomb, EyePoint Pharmaceuticals, Genentech, Glaukos, Neurotech Pharmaceuticals and Ocular Therapeutix.

Question 5: How many patents have been filed / granted related to the ocular drug delivery devices till date?

Answer: Over 1,100 patents have been filed / granted related to the ocular drugs delivery devices till date.

Question 6: How many devices are currently marketed / under development by companies engaged in the ocular drug delivery devices market?

Answer: More than 45 devices are currently marketed / under development by companies engaged in the ocular drug delivery devices market.

Question 7: Which region emerged as the hub for companies engaged in the ocular drug delivery devices market?

Answer: North America emerged as the hub for companies engaged in the ocular drug delivery system market, with 75% of the players established in the region.